C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. 2017

María-Salud García-Ayllón, and Inmaculada Lopez-Font, and Claudia P Boix, and Juan Fortea, and Raquel Sánchez-Valle, and Alberto Lleó, and José-Luis Molinuevo, and Henrik Zetterberg, and Kaj Blennow, and Javier Sáez-Valero
Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, 03550, Sant Joan d'Alacant, Alicante, España.

This study assesses whether C-terminal fragments (CTF) of the amyloid precursor protein (APP) are present in cerebrospinal fluid (CSF) and their potential as biomarkers for Alzheimer's disease (AD). Immunoprecipitation and simultaneous assay by Western blotting using multiplex fluorescence imaging with specific antibodies against particular domains served to characterize CTFs of APP in human CSF. We demonstrate that APP-CTFs are detectable in human CSF, being the most abundant a 25-kDa fragment, probably resulting from proteolytic processing by η-secretase. The level of the 25-kDa APP-CTF was evaluated in three independent CSF sample sets of patients and controls. The CSF level of this 25-kDa CTF is higher in subjects with autosomal dominant AD linked to PSEN1 mutations, in demented Down syndrome individuals and in sporadic AD subjects compared to age-matched controls. Our data suggest that APP-CTF could be a potential diagnostic biomarker for AD.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D003704 Dementia An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness. Senile Paranoid Dementia,Amentia,Familial Dementia,Amentias,Dementia, Familial,Dementias,Dementias, Familial,Dementias, Senile Paranoid,Familial Dementias,Paranoid Dementia, Senile,Paranoid Dementias, Senile,Senile Paranoid Dementias
D004314 Down Syndrome A chromosome disorder associated either with an extra CHROMOSOME 21 or an effective TRISOMY for chromosome 21. Clinical manifestations include HYPOTONIA, short stature, BRACHYCEPHALY, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, single transverse palmar crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213) Mongolism,Trisomy 21,47,XX,+21,47,XY,+21,Down Syndrome, Partial Trisomy 21,Down's Syndrome,Partial Trisomy 21 Down Syndrome,Trisomy 21, Meiotic Nondisjunction,Trisomy 21, Mitotic Nondisjunction,Trisomy G,Downs Syndrome,Syndrome, Down,Syndrome, Down's
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia

Related Publications

María-Salud García-Ayllón, and Inmaculada Lopez-Font, and Claudia P Boix, and Juan Fortea, and Raquel Sánchez-Valle, and Alberto Lleó, and José-Luis Molinuevo, and Henrik Zetterberg, and Kaj Blennow, and Javier Sáez-Valero
January 2012, Journal of Alzheimer's disease : JAD,
María-Salud García-Ayllón, and Inmaculada Lopez-Font, and Claudia P Boix, and Juan Fortea, and Raquel Sánchez-Valle, and Alberto Lleó, and José-Luis Molinuevo, and Henrik Zetterberg, and Kaj Blennow, and Javier Sáez-Valero
June 2010, Experimental neurology,
María-Salud García-Ayllón, and Inmaculada Lopez-Font, and Claudia P Boix, and Juan Fortea, and Raquel Sánchez-Valle, and Alberto Lleó, and José-Luis Molinuevo, and Henrik Zetterberg, and Kaj Blennow, and Javier Sáez-Valero
January 2019, PloS one,
María-Salud García-Ayllón, and Inmaculada Lopez-Font, and Claudia P Boix, and Juan Fortea, and Raquel Sánchez-Valle, and Alberto Lleó, and José-Luis Molinuevo, and Henrik Zetterberg, and Kaj Blennow, and Javier Sáez-Valero
January 2000, Journal of neural transmission. Supplementum,
María-Salud García-Ayllón, and Inmaculada Lopez-Font, and Claudia P Boix, and Juan Fortea, and Raquel Sánchez-Valle, and Alberto Lleó, and José-Luis Molinuevo, and Henrik Zetterberg, and Kaj Blennow, and Javier Sáez-Valero
March 1991, Neuroscience letters,
María-Salud García-Ayllón, and Inmaculada Lopez-Font, and Claudia P Boix, and Juan Fortea, and Raquel Sánchez-Valle, and Alberto Lleó, and José-Luis Molinuevo, and Henrik Zetterberg, and Kaj Blennow, and Javier Sáez-Valero
February 2010, Molecular psychiatry,
María-Salud García-Ayllón, and Inmaculada Lopez-Font, and Claudia P Boix, and Juan Fortea, and Raquel Sánchez-Valle, and Alberto Lleó, and José-Luis Molinuevo, and Henrik Zetterberg, and Kaj Blennow, and Javier Sáez-Valero
October 1995, Neuroscience letters,
María-Salud García-Ayllón, and Inmaculada Lopez-Font, and Claudia P Boix, and Juan Fortea, and Raquel Sánchez-Valle, and Alberto Lleó, and José-Luis Molinuevo, and Henrik Zetterberg, and Kaj Blennow, and Javier Sáez-Valero
April 1992, Proceedings of the National Academy of Sciences of the United States of America,
María-Salud García-Ayllón, and Inmaculada Lopez-Font, and Claudia P Boix, and Juan Fortea, and Raquel Sánchez-Valle, and Alberto Lleó, and José-Luis Molinuevo, and Henrik Zetterberg, and Kaj Blennow, and Javier Sáez-Valero
August 1989, Proceedings of the National Academy of Sciences of the United States of America,
María-Salud García-Ayllón, and Inmaculada Lopez-Font, and Claudia P Boix, and Juan Fortea, and Raquel Sánchez-Valle, and Alberto Lleó, and José-Luis Molinuevo, and Henrik Zetterberg, and Kaj Blennow, and Javier Sáez-Valero
January 2015, Molecular neurodegeneration,
Copied contents to your clipboard!